凯利泰(300326) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 264.81 million, an increase of 7.56% compared to CNY 246.21 million in the same period last year[7]. - Net profit attributable to shareholders was CNY 21.76 million, representing a 100.03% increase from CNY 10.88 million year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 20.10 million, up 141.84% from CNY 8.31 million in the previous year[7]. - The company’s operating profit and total profit for Q1 2025 were CNY 30.07 million and CNY 30.11 million, respectively, reflecting growth of 53.30% and 53.70% year-on-year[11]. - Total operating revenue for the current period reached ¥264,814,699.46, an increase of 7.0% compared to ¥246,205,033.77 in the previous period[36]. - Net profit for the current period was ¥25,914,508.10, representing a significant increase of 56.5% from ¥16,554,844.75 in the previous period[36]. - The total comprehensive income for the period was CNY 24,741,946.44, compared to CNY 17,866,526.38 in the previous period, representing an increase of approximately 38.5%[38]. Cash Flow - The net cash flow from operating activities was CNY 8.51 million, a significant improvement of 143.65% compared to a negative cash flow of CNY 19.50 million in the same period last year[7]. - The net cash flow from investment activities improved by CNY 16.86 million, reaching -CNY 7.53 million compared to -CNY 24.39 million in the same period last year[26]. - The net cash flow from financing activities was -22.2481 million yuan, a decrease of 31.5657 million yuan compared to the same period last year, primarily due to a reduction in net bank borrowings by 39.8399 million yuan[27]. - The cash inflow from investment activities was CNY 316,947,727.48, compared to CNY 242,065,569.77 in the previous period, marking an increase of about 31%[41]. - The total cash outflow from investment activities was CNY 392,223,062.87, down from CNY 485,919,004.65 in the previous period, indicating a reduction of approximately 19.3%[41]. - The company reported a net increase in cash and cash equivalents of CNY -89,086,230.35 for the period, compared to a net decrease of CNY -253,847,513.70 in the previous period[41]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3.34 billion, a slight decrease of 0.41% from CNY 3.35 billion at the end of the previous year[7]. - Current liabilities decreased to ¥395,549,959.22 from ¥441,227,382.43, a reduction of 10.4%[34]. - Long-term borrowings increased to ¥10,114,434.77 from ¥9,507,331.35, reflecting a rise of 6.4%[34]. - The company's total equity rose to ¥2,851,868,469.47 from ¥2,818,873,837.76, an increase of 1.2%[34]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,248, with no preferred shareholders having restored voting rights[29]. - The top 10 shareholders held a total of 6.99% (50,100,000 shares) by Yongjin Investment Holdings, and 5.03% (36,050,241 shares) by Shanghai Xincheng Yitou[29]. - There were no significant changes in the top 10 shareholders' participation in margin trading or securities lending activities[30]. - The company has not reported any changes in the number of preferred shareholders or any significant changes in restricted shares[31]. Investment Activities - The company reported a significant increase in investment activity cash inflows, totaling CNY 31.69 million, a 30.93% increase from CNY 24.21 million in the previous year[25]. - The company received CNY 7,534,725.66 from minority shareholders as part of investment inflow[41]. - The company’s subsidiary, Jieno Medical, received minority shareholder capital contributions of 7.5347 million yuan during the reporting period[27]. - The company paid minority shareholder profits of 1.0599 million yuan through its subsidiary Shenyang Kailitai during the reporting period[27]. Other Financial Metrics - Basic and diluted earnings per share increased to CNY 0.0303, up 99.34% from CNY 0.0152 year-on-year[7]. - Research and development expenses were ¥12,348,782.57, down from ¥14,979,793.67, a decrease of 17.5%[37]. - The company reported an investment income of ¥634,460.72, a recovery from a loss of ¥2,447,816.57 in the previous period[37]. - The company's cash and cash equivalents were not explicitly detailed, but the overall liquidity position appears stable given the reduction in current liabilities[34]. - Cash and cash equivalents at the end of the period decreased to CNY 232,028,770.15 from CNY 361,137,590.27, a decline of approximately 35.7%[41]. - The trading financial assets increased to 876,860,830.95 yuan from 841,430,441.46 yuan at the beginning of the period[32]. Audit and Reporting - The company did not undergo an audit for the first quarter report[42]. - The company has not disclosed any new product developments or market expansion strategies in the provided content[31].